Since contemporarily used anti-angiogenic drugs, based on the blockade of vascular endothelial growth factor (VEGF) signaling pathway, so far have not displayed a clinically significant benefit either as monotherapy or as a combined anticancer treatment, other methods of endothelial cell inhibition are still sought as valuable new approach to cancer therapy [152,153]. This evidence concerns the gene VEGFA and cancer.